Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Consensus PT from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $16.75.

Several brokerages have recently issued reports on FOLD. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Wells Fargo & Company reduced their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $7.99 on Monday. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -44.39, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. Amicus Therapeutics has a 52-week low of $7.85 and a 52-week high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The stock has a 50 day moving average price of $9.19 and a 200 day moving average price of $9.90.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. HealthInvest Partners AB raised its stake in shares of Amicus Therapeutics by 18.6% during the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock worth $3,076,000 after purchasing an additional 51,368 shares during the last quarter. Wellington Management Group LLP increased its stake in Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after buying an additional 2,856,101 shares during the period. Tempus Wealth Planning LLC purchased a new position in Amicus Therapeutics during the 4th quarter worth $259,000. Neo Ivy Capital Management acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $702,000. Finally, Intech Investment Management LLC boosted its holdings in shares of Amicus Therapeutics by 59.7% in the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company’s stock valued at $1,175,000 after acquiring an additional 46,633 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.